Tuberculosis vaccines: beyond bacille Calmette–Guérin

Tuberculosis (TB) disease caused by Mycobacterium tuberculosis (M. tb) remains one of the leading infectious causes of death and disease throughout the world. The only licensed vaccine, Mycobacterium bovis bacille Calmette–Guérin (BCG) confers highly variable protection against pulmonary disease. An effective vaccination regimen would be the most efficient way to control the epidemic. However, BCG does confer consistent and reliable protection against disseminated disease in childhood, and most TB vaccine strategies being developed incorporate BCG to retain this protection. Cellular immunity is necessary for protection against TB and all the new vaccines in development are focused on inducing a strong and durable cellular immune response. There are two main strategies being pursued in TB vaccine development. The first is to replace BCG with an improved whole organism mycobacterial priming vaccine, which is either a recombinant BCG or an attenuated strain of M. tb. The second is to develop a subunit boosting vaccine, which is designed to be administered after BCG vaccination, and to enhance the protective efficacy of BCG. This article reviews the leading candidate vaccines in development and considers the current challenges in the field with regard to efficacy testing.

• Publication year

  2011

• Venue

  Philosophical Transactions of the Royal Society B: Biological Sciences

• Publication date

  2011-10-12

• Fields of study

  Medicine

• Identifiers
  DOI 10.1098/rstb.2011.0097PMID 21893541PMCID 3146779
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Fortsetzung der Mitteilungen über ein Heilmittel gegen Tuberkulose

  2010cited by this paper
• Specific T cell frequency and cytokine expression profile do not correlate with protection against tuberculosis after bacillus Calmette-Guérin vaccination of newborns.

  2010cited by this paper
• The novel tuberculosis vaccine, AERAS-402, induces robust and polyfunctional CD4+ and CD8+ T cells in adults.

  2010cited by this paper
• Evaluation of the Safety and Immunogenicity of Two Antigen Concentrations of the Mtb72F/AS02A Candidate Tuberculosis Vaccine in Purified Protein Derivative-Negative Adults

  2010cited by this paper
• Specific T cell Frequency and Cytokine Expression Profile Do Not Correlate with Protection against Tuberculosis, Following BCG Vaccination of Newborns

  2010cited by this paper
• The second Geneva Consensus: Recommendations for novel live TB vaccines.

  2010cited by this paper
• Prevention of tuberculosis in Bacille Calmette–Guérin-primed, HIV-infected adults boosted with an inactivated whole-cell mycobacterial vaccine

  2010cited by this paper
• Ag85B-ESAT-6 adjuvanted with IC31 promotes strong and long-lived Mycobacterium tuberculosis specific T cell responses in naïve human volunteers.

  2010cited by this paper
• Novel recombinant BCG expressing perfringolysin O and the over-expression of key immunodominant antigens; pre-clinical characterization, safety and protection against challenge with Mycobacterium tuberculosis.

  2009cited by this paper
• Viral Booster Vaccines Improve Mycobacterium bovis BCG-Induced Protection against Bovine Tuberculosis

  2009cited by this paper
• The candidate tuberculosis vaccine Mtb72F/AS02A: Tolerability and immunogenicity in humans

  2009cited by this paper
• Safety and Immunogenicity of Boosting BCG Vaccinated Subjects with BCG: Comparison with Boosting with a New TB Vaccine, MVA85A

  2009cited by this paper
• MVA.85A Boosting of BCG and an Attenuated, phoP Deficient M. tuberculosis Vaccine Both Show Protective Efficacy Against Tuberculosis in Rhesus Macaques

  2009cited by this paper
• Modified vaccinia Ankara‐expressing Ag85A, a novel tuberculosis vaccine, is safe in adolescents and children, and induces polyfunctional CD4+ T cells

  2009cited by this paper
• Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in Mycobacterium tuberculosis-infected individuals.

  2009cited by this paper
• Efficacy and safety of live attenuated persistent and rapidly cleared Mycobacterium tuberculosis vaccine candidates in non-human primates.

  2009cited by this paper
• Efficacy of percutaneous versus intradermal BCG in the prevention of tuberculosis in South African infants: randomised trial

  2008cited by this paper
• Safety and immunogenicity of a new tuberculosis vaccine, MVA85A, in healthy adults in South Africa.

  2008cited by this paper
• Safety and Immunogenicity of the Candidate Tuberculosis Vaccine MVA85A in West Africa

  2008cited by this paper
• rBCG Induces Strong Antigen-Specific T Cell Responses in Rhesus Macaques in a Prime-Boost Setting with an Adenovirus 35 Tuberculosis Vaccine Vector

  2008cited by this paper
• A new recombinant bacille Calmette-Guérin vaccine safely induces significantly enhanced tuberculosis-specific immunity in human volunteers.

  2008cited by this paper
• Protective Immune Responses to a Recombinant Adenovirus Type 35 Tuberculosis Vaccine in Two Mouse Strains: CD4 and CD8 T-Cell Epitope Mapping and Role of Gamma Interferon

  2007cited by this paper
• Poor correlation between BCG vaccination-induced T cell responses and protection against tuberculosis

  2007cited by this paper
• IL-23 and IL-17 in the establishment of protective pulmonary CD4+ T cell responses after vaccination and during Mycobacterium tuberculosis challenge

  2007cited by this paper
• Vaccination of cattle with Danish and Pasteur strains of Mycobacterium bovis BCG induce different levels of IFNgamma post-vaccination, but induce similar levels of protection against bovine tuberculosis.

  2007cited by this paper
• Boosting BCG with Recombinant Modified Vaccinia Ankara Expressing Antigen 85A: Different Boosting Intervals and Implications for Efficacy Trials

  2007cited by this paper
• Immunisation with BCG and recombinant MVA85A induces long‐lasting, polyfunctional Mycobacterium tuberculosis‐specific CD4+ memory T lymphocyte populations

  2007cited by this paper
• The risk of disseminated Bacille Calmette-Guerin (BCG) disease in HIV-infected children.

  2007cited by this paper
• The live Mycobacterium tuberculosis phoP mutant strain is more attenuated than BCG and confers protective immunity against tuberculosis in mice and guinea pigs.

  2006cited by this paper
• The Global Plan to Stop TB, 2006-2015.

  2006cited by this paper
• Chimpanzee Adenovirus Antibodies in Humans, Sub-Saharan Africa

  2006cited by this paper
• Mucosal Administration of Ag85B-ESAT-6 Protects against Infection with Mycobacterium tuberculosis and Boosts Prior Bacillus Calmette-Guérin Immunity1

  2006cited by this paper
• Effect of BCG vaccination on childhood tuberculous meningitis and miliary tuberculosis worldwide: a meta-analysis and assessment of cost-effectiveness.

  2006cited by this paper
• Effect of BCG revaccination on incidence of tuberculosis in school-aged children in Brazil: the BCG-REVAC cluster-randomised trial.

  2005cited by this paper
• New live mycobacterial vaccines: the Geneva consensus on essential steps towards clinical development.

  2005cited by this paper
• Exchanging ESAT6 with TB10.4 in an Ag85B Fusion Molecule-Based Tuberculosis Subunit Vaccine: Efficient Protection and ESAT6-Based Sensitive Monitoring of Vaccine Efficacy 1

  2005cited by this paper
• Increased vaccine efficacy against tuberculosis of recombinant Mycobacterium bovis bacille Calmette-Guérin mutants that secrete listeriolysin.

  2005cited by this paper
• Evaluation of vaccines in the EU TB Vaccine Cluster using a guinea pig aerosol infection model of tuberculosis.

  2005cited by this paper
• Boosting with Poxviruses Enhances Mycobacterium bovis BCG Efficacy against Tuberculosis in Guinea Pigs

  2005cited by this paper
• Adenovirus types 5 and 35 seroprevalence in AIDS risk groups supports type 35 as a vaccine vector

  2004cited by this paper
• Recombinant modified vaccinia virus Ankara expressing antigen 85A boosts BCG-primed and naturally acquired antimycobacterial immunity in humans

  2004cited by this paper
• Interferon-gamma assays in the immunodiagnosis of tuberculosis: a systematic review.

  2004cited by this paper
• Differential Immune Responses and Protective Efficacy Induced by Components of a Tuberculosis Polyprotein Vaccine, Mtb72F, Delivered as Naked DNA or Recombinant Protein1

  2004cited by this paper
• Central memory and effector memory T cell subsets: function, generation, and maintenance.

  2004cited by this paper
• Interferon-γ assays in the immunodiagnosis of tuberculosis: a systematic review

  2004cited by this paper
• Anti-tumour necrosis factor agents and tuberculosis risk: mechanisms of action and clinical management.

  2003cited by this paper
• Immunology of tuberculosis.

  2003cited by this paper
• Recombinant Modified Vaccinia Virus Ankara Administration and Boosting with a Bacille Calmette-Guérin Vaccine Using Mucosal of Mycobacterium tuberculosis Efficacy Against Enhanced Immunogenicity and Protective

  2003cited by this paper
• Enhanced Immunogenicity and Protective Efficacy Against Mycobacterium tuberculosis of Bacille Calmette-Guérin Vaccine Using Mucosal Administration and Boosting with a Recombinant Modified Vaccinia Virus Ankara1

  2003cited by this paper
• The growing burden of tuberculosis: global trends and interactions with the HIV epidemic.

  2003cited by this paper
• Development of vaccines to control bovine tuberculosis in cattle and relationship to vaccine development for other intracellular pathogens.

  2003cited by this paper
• Pulmonary Necrosis Resulting from DNA Vaccination against Tuberculosis

  2003cited by this paper
• Evolution of Epitope-Specific Memory CD4+ T Cells After Clearance of Hepatitis C Virus

  2002cited by this paper
• Divergent effect of bacillus Calmette–Guérin (BCG) vaccination on Mycobacterium tuberculosis infection in highly related macaque species: Implications for primate models in tuberculosis vaccine research

  2001cited by this paper
• More than one way to go.

  2001cited by this paper
• Relative contributions of distinct MHC class I-dependent cell populations in protection to tuberculosis infection in mice.

  2000cited by this paper
• On Evaluation of Safety

  2000cited by this paper
• Recombinant bacillus calmette-guerin (BCG) vaccines expressing the Mycobacterium tuberculosis 30-kDa major secretory protein induce greater protective immunity against tuberculosis than conventional BCG vaccines in a highly susceptible animal model.

  2000cited by this paper
• Double-blind placebo-controlled trial of Mycobacterium vaccae immunotherapy for tuberculosis in KwaZulu, South Africa, 1991-97.

  2000cited by this paper
• Control of latent Mycobacterium tuberculosis infection is dependent on CD8 T cells

  2000cited by this paper
• Mice deficient in CD4 T cells have only transiently diminished levels of IFN-gamma, yet succumb to tuberculosis.

  1999cited by this paper
• Does the efficacy of BCG decline with time since vaccination?

  1998cited by this paper
• Tumor necrosis factor alpha.

  1998cited by this paper
• A mutation in the interferon-gamma-receptor gene and susceptibility to mycobacterial infection.

  1996cited by this paper
• Tumor necrosis factor-alpha is required in the protective immune response against Mycobacterium tuberculosis in mice.

  1995cited by this paper
• Efficacy of BCG vaccine in the prevention of tuberculosis. Meta-analysis of the published literature.

  1994cited by this paper
• Efficacy of BCG Vaccine in the Prevention of Tuberculosis: Meta-analysis of the Published Literature

  1994cited by this paper
• Protective effect of BCG against tuberculous meningitis and miliary tuberculosis: a meta-analysis.

  1993cited by this paper
• An essential role for interferon gamma in resistance to Mycobacterium tuberculosis infection

  1993cited by this paper
• Tumor necrosis factor-a

  1991cited by this paper
• Mycobacterium vaccae in immunoprophylaxis and immunotherapy of leprosy and tuberculosis.

  1990cited by this paper
• BCG vaccination of children against leprosy in Uganda: final results

  1981cited by this paper
• [The smallpox vaccination strain MVA: marker, genetic structure, experience gained with the parenteral vaccination and behavior in organisms with a debilitated defence mechanism (author's transl)].

  1978cited by this paper
• Prevention of Tuberculosis*

  1952cited by this paper
• Fortsetzung der Mittheilungen über ein Heilmittel gegen Tuberculose

  1891cited by this paper

• Advancement of functional peptides: Promising candidates for antituberculosis therapeutics

  2026cites this paper
• Oral delivery of Mycobacterium bovis bacillus Calmette-Guérin (BCG) in alginate spheres to captive white-tailed deer

  2025cites this paper
• Strong immune responses and robust protection following a novel protein in adjuvant tuberculosis vaccine candidate

  2025cites this paper
• Enhanced Antimicrobial Peptide Response Following Bacillus Calmette–Guerin Vaccination in Elderly Individuals

  2024cites this paper
• Immunogenic profiling of Mycobacterium tuberculosis Rv1513 reveals its ability to switch on Th1 based immunity

  2024cites this paper
• Construction and expression of Mycobacterium tuberculosis fusion protein SHR3 and its immunogenicity analysis in combination with various adjuvants.

  2024cites this paper
• Mycobacterium tuberculosis strain with deletions in menT3 and menT4 is attenuated and confers protection in mice and guinea pigs

  2024cites this paper
• A Multistage Antigen Complex Epera013 Promotes Efficient and Comprehensive Immune Responses in BALB/c Mice

  2023cites this paper
• Over 90% of Childhood BCG Vaccine-Induced Keloids in Japan Occur in Women

  2023cites this paper
• Comparison of two mycobacterial strains in performance of the whole blood mycobacterial growth inhibition assay in Indian children.

  2022cites this paper
• Cyclic di-AMP as endogenous adjuvant enhanced BCG-induced trained immunity and protection against Mycobacterium tuberculosis in mice

  2022cites this paper
• Past, Present and Future of Bacillus Calmette-Guérin Vaccine Use in China

  2022cites this paper
• Impact of Mycobacterium tuberculosis Infection on Human B Cell Compartment and Antibody Responses

  2022cites this paper
• Pathogenicity and virulence of Mycobacterium tuberculosis

  2022cites this paper
• Scientific Progress of Global Research on BCG Vaccine: A Scientometric Study

  2022cites this paper
• A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line anti-tuberculosis regimen.

  2021cites this paper
• The safety and efficacy of BCG encapsulated alginate particle (BEAP) against M.tb H37Rv infection in Macaca mulatta : A pilot study

  2021cites this paper
• A recombinant selective drug-resistant M. bovis BCG enhances the bactericidal activity of a second-line tuberculosis regimen

  2021cites this paper
• Recombinant BCGs for tuberculosis and bladder cancer.

  2021cites this paper
• BCG turns 100: its nontraditional uses against viruses, cancer, and immunologic diseases.

  2021cites this paper
• Immunological Characterization of Proteins Expressed by Genes Located in Mycobacterium tuberculosis-Specific Genomic Regions Encoding the ESAT6-like Proteins

  2021cites this paper
• The double-sided effects of Mycobacterium Bovis bacillus Calmette–Guérin vaccine

  2021cites this paper
• Immunotherapies For Cancer, a Promising Cure?

  2020cites this paper
• Proposing BCG Vaccination for Mycobacterium avium ss. paratuberculosis (MAP) Associated Autoimmune Diseases

  2020cites this paper
• BCG Vaccination: A Beacon Of Hope With A Word Of Caution – An Overview On The Current Consensus In ncovid-19

  2020cites this paper
• Natural Resistance to and Host-Directed Prevention of Tuberculosis

  2020cites this paper
• Animal Models of Tuberculosis Vaccine Research: An Important Component in the Fight against Tuberculosis

  2020cites this paper
• Systematic Evaluation of Mycobacterium tuberculosis Proteins for Antigenic Properties Identifies Rv1485 and Rv1705c as Potential Protective Subunit Vaccine Candidates

  2020cites this paper
• Chemoenzymatic synthesis of arabinomannan (AM) glycoconjugates as potential vaccines for tuberculosis.

  2020cites this paper
• Transposon libraries identify novel Mycobacterium bovis BCG genes involved in the dynamic interactions required for BCG to persist during in vivo passage in cattle

  2019cites this paper
• Newborn BCG Vaccinations: Scar Formation and Tuberculin Conversion Rates: A Retrospective Study

  2019cites this paper
• Vaccine development: A historical perspective.

  2019cites this paper
• The comeback kid: BCG.

  2019cites this paper
• The current status of bacillus Calmette‐Guérin vaccine protective efficacy

  2019cites this paper
• Mar-Apr 2019 An Overview on Tuberculosis ( TB )

  2019cites this paper
• Recombinant BCG expressing the LTAK63 adjuvant induces increased early and long-term immune responses against Mycobacteria

  2019cites this paper
• Tuberculosis: Current Status, Diagnosis, Treatment and Development of Novel Vaccines.

  2019cites this paper
• A Statistical Investigation to Determine the Predisposing Risk Factors for Predicting Prevalence of Active Tuberculosis in North Pokot Sub County, West Pokot County, Kenya

  2018cites this paper
• Mass spectrometry-based analysis of the HLA-ligandomes of renal cell carcinoma and benign renal tissue

  2018cites this paper
• The development of a mathematical modelling framework to translate TB vaccine responses between species and predict the most immunogenic dose in humans using animal data

  2018cites this paper
• Managing Recalcitrant Warts: Facts about Bacillus Calmette-Guerin (BCG), Mycobacterium Indicus Pranii (Mw Vaccine), and Purified Protein Derivative (PPD) as Immunotherapy

  2018cites this paper
• A mathematical model of TB control with vaccination in an age-structured susceptible population

  2018cites this paper
• Identification and Evaluation of Novel Protective Antigens for the Development of a Candidate Tuberculosis Subunit Vaccine

  2018cites this paper
• Lessons from the first clinical trial of a non-licensed vaccine among Ugandan adolescents: a phase II field trial of the tuberculosis candidate vaccine, MVA85A

  2018cites this paper
• Comparison of immunogenicity and vaccine efficacy between heat-shock proteins, HSP70 and GrpE, in the DnaK operon of Mycobacterium tuberculosis

  2018cites this paper
• Future Path Toward TB Vaccine Development: Boosting BCG or Re-educating by a New Subunit Vaccine

  2018cites this paper
• Evaluation of DNA vaccines encoding M. Tb gene Bfrb and Mpt32 in mice model.

  2017cites this paper
• TUBERCULOSIS VACCINES: CURRENT STATE AND FUTURE DIRECTIONS

  2017cites this paper
• Isolation, cloning and molecular analysis of ag85a and tb10.4 genes from Mycobacterium tuberculosis

  2017influential citation
• Diterpenes as lead molecules against neglected tropical diseases

  2017cites this paper
• Characterization of LYTM domain containing proteins in mycobacterium smegmatis

  2017cites this paper
• Role and contribution of pulmonary CD103+ dendritic cells in the adaptive immune response to Mycobacterium tuberculosis.

  2017cites this paper
• Evolution and Strain Variation in BCG.

  2017cites this paper
• Addressing the Challenges of Tuberculosis: A Brief Historical Account

  2017influential citation
• Synthesis and Immunological Studies of the Lipomannan Backbone Glycans Found on the Surface of Mycobacterium tuberculosis.

  2017cites this paper
• Vaccine research and development: tuberculosis as a global health threat

  2017cites this paper
• Mycobacterial L-forms are found in cord blood: A potential vertical transmission of BCG from vaccinated mothers

  2016cites this paper
• Selective presentation of MVA85A tuberculosis booster vaccine preclinical animal data.

  2016cites this paper
• Mycobacterium tuberculosis PE9 protein has high activity binding peptides which inhibit target cell invasion.

  2016cites this paper
• TB Vaccine Assessment

  2016cites this paper
• Vaccine Preparation: Past, Present, and Future

  2016cites this paper
• Evolution of XDR-TB and the associated proteome

  2016cites this paper
• Directed Intervention and Immunomodulation against Pulmonary Tuberculosis

  2016cites this paper
• DNA vaccination boosts Bacillus Calmette-Guérin protection against mycobacterial infection in zebrafish.

  2016cites this paper
• Vaccines against tuberculosis: A review.

  2016influential citation
• Protection associated with a TB vaccine is linked to increased frequency of Ag85A-specific CD4+ T cells but no increase in avidity for Ag85A

  2016cites this paper
• T cell recall response of two hypothetical proteins (Rv2251 and Rv2721c) from Mycobacterium tuberculosis in healthy household contacts of TB - Possible subunit vaccine candidates.

  2016cites this paper
• HIV-1 Subtype C Mosaic Gag Expressed by BCG and MVA Elicits Persistent Effector T Cell Responses in a Prime-Boost Regimen in Mice

  2016cites this paper
• An Update on New Vaccines for Tuberculosis

  2016cites this paper
• Emerging drugs and alternative possibilities in the treatment of tuberculosis

  2016cites this paper
• Individual-level factors associated with variation in mycobacterial-specific immune response: Gender and previous BCG vaccination status.

  2016cites this paper
• Gene expression profiling identifies candidate biomarkers for active and latent tuberculosis

  2016influential citation
• Immunoprophylaxis in Guinea Pigs with Mycobacterium indicus pranii (Mw) in Combination with Standard Chemotherapy of M. tuberculosis Infection ImprovesLung Pathology

  2016cites this paper
• Ancient Disease, Modern Epidemiology: A Century of Progress in Understanding and Fighting Tuberculosis.

  2016cites this paper
• Duration of BCG protection against tuberculosis and change in effectiveness with time since vaccination in Norway: a retrospective population-based cohort study.

  2016cites this paper
• Construction and evaluation of three candidate vaccines expressing HIV-1 subtype-C mosaic Gag

  2015cites this paper
• DNA-Launched Alphavirus Replicons Encoding a Fusion of Mycobacterial Antigens Acr and Ag85B Are Immunogenic and Protective in a Murine Model of TB Infection

  2015cites this paper
• Protective capacity of proteoliposomes from Mycobacterium bovis BCG in a mouse model of tuberculosis

  2015cites this paper
• Tackling tuberculosis: Insights from an international TB Summit in London

  2015cites this paper
• Dendritic Cell Activity Driven by Recombinant Mycobacterium bovis BCG Producing Human IL-18, in Healthy BCG Vaccinated Adults

  2015cites this paper
• Absence of Annexin A1 impairs host adaptive immunity against Mycobacterium tuberculosis in vivo.

  2015cites this paper
• Rhodococcus equi (Prescottella equi) vaccines; the future of vaccine development.

  2015cites this paper
• The Tuberculosis Vaccines Pipeline : A New Path to the Same Destination ?

  2015cites this paper
• Combination radiofrequency ablation and local injection of the immunostimulant bacillus Calmette-Guérin induces antitumor immunity in the lung and at a distant VX2 tumor in a rabbit model.

  2015cites this paper
• BCG and Autoimmunity

  2015cites this paper
• The role of whole-genome sequencing technology in the control and treatment of Mycobacterium tuberculosis infection

  2015cites this paper
• Immunology studies in non‐human primate models of tuberculosis

  2015cites this paper
• Interpreting measures of tuberculosis transmission: a case study on the Portuguese population

  2014cites this paper
• Update on cutaneous tuberculosis

  2014cites this paper
• Revista6Vol89ingles_Layout 1

  2014cites this paper
• Clinical presentation of tuberculosis in adolescents as seen at National Hospital Abuja, Nigeria

  2014cites this paper
• Role of the CD137 ligand (CD137L) signaling pathway during Mycobacterium tuberculosis infection.

  2014cites this paper
• Comparison of the immunogenicity and protection against bovine tuberculosis following immunization by BCG-priming and boosting with adenovirus or protein based vaccines.

  2014cites this paper
• Multidrug resistant tuberculosis: A challenge in clinical orthopedics

  2014cites this paper
• Modelling the cost-effectiveness of a new infant vaccine to prevent tuberculosis disease in children in South Africa

  2014cites this paper
• Vaccines against poverty

  2014cites this paper
• Integrative immunoinformatics for Mycobacterial diseases in R platform

  2014cites this paper
• Prime–boost bacillus Calmette–Guérin vaccination with lentivirus‐vectored and DNA‐based vaccines expressing antigens Ag85B and Rv3425 improves protective efficacy against Mycobacterium tuberculosis in mice

  2014cites this paper
• Host immune responses to mycobacterial antigens and their implications for the development of a vaccine to control tuberculosis

  2014cites this paper
• The role of B cells and humoral immunity in Mycobacterium tuberculosis infection.

  2014cites this paper